NEPHROS INC · Surgical & Medical Instruments & Apparatus

NEPH

Low riskNext report: Around Nov 9 (est.)

View price ↗

The short version

A profitable company with growing sales.

Going well

Sales up 36% in the latest quarter vs a year ago
Profitable
Sales up 33% last year

Money moves

No insider buying or selling in the last 30 days
Institutions cut 1.1% from their holdings in the quarter ending June 2026 (14 bought, 10 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$3.59+0.3% that day

Company value: $39M; Share price times all shares
Price vs profit (P/E): 22.4x; You pay about $22 for each $1 of yearly profit
Price vs sales: 1.9x; Company value is 1.9 times a year of sales
Cash vs value: 12%; Cash as a share of company value

From NEPH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$6.0M+36% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $20.7M, up 24% from the 12 months before. Over 5 years, sales grew about 17% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of NEPH. Starting points are the company's recent numbers.

Sales growth+24% a yearRecently: +24% a yearProfit margin8%Last 12 months: 8.4%P/E at the end22xToday: 22.4x. Many steady companies trade at 12x to 25xShare count change+2% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$61M

Profit in 5 years$5M

Price these guesses point to$8.92+148% vs $3.59 todayAbout +20% a year, before dividends

What today's price needs: with a 8% margin and a 22x P/E, sales would have to grow about 3.4% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/6Mixed

PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.6.4%
MissProfitable every yearSteady profits, not one good year.2 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$1.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+6.5% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.61.9%

Revenue: $18.8M; +32.7% vs prior year
5-year growth: +17.0%/yr; revenue, per year
Total debt: None
Current ratio: 4.06x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+. A checklist is a starting point for research, not a verdict.